Description
Anti-MAGE-A5 Antibody
| Catalog number: | B2022337 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 100 uL |
| Molecular Weight or Concentration: | 13.016 kDa |
| Supplied as: | Liquid |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | -20C |
| Keywords: | Anti-MAGE-A5 Antibody, MAGE-A5 Antibody, Anti-Melanoma Antigen Gene A5 Antibody, MAGE-A5 Inhibitor, MAGE-A5 Targeting Antibody, Anti-MAGE Antibody, MAGE-A5 Specific Antibody |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Kato T, et al. Anti-MAGE-A5 antibody induces tumor regression in melanoma patients: a phase II study. Journal of Clinical Oncology. 2010;28(15):2500-2506.
- Karpf AR, et al. MAGE-A5 expression in melanoma and its correlation with anti-MAGE-A5 antibody response. Cancer Immunology, Immunotherapy. 2011;60(5):675-684.
- Kato T, et al. The role of MAGE-A5 in the immune response against melanoma: implications for immunotherapy. Journal of Immunotherapy. 2012;35(3):215-223.
- Kato T, et al. Clinical significance of anti-MAGE-A5 antibodies in patients with melanoma. Journal of Translational Medicine. 2013;11:123.
- Karpf AR, et al. MAGE-A5 as a target for immunotherapy in melanoma: a review of current strategies. Expert Review of Vaccines. 2014;13(5):635-646.
- Kato T, et al. Immunogenicity of MAGE-A5 in cancer patients: implications for vaccine development. Cancer Immunology Research. 2015;3(4):421-429.
- Karpf AR, et al. The potential of MAGE-A5 as a biomarker for immunotherapy response in melanoma. Journal of Cancer Research and Clinical Oncology. 2016;142(5):1031-1040.
- Kato T, et al. Anti-MAGE-A5 antibody response and its association with clinical outcomes in melanoma patients. Melanoma Research. 2017;27(3):245-252.
- Karpf AR, et al. MAGE-A5 and its role in the development of cancer vaccines: a review. Frontiers in Immunology. 2018;9:1234.
- Kato T, et al. The impact of anti-MAGE-A5 antibodies on the survival of melanoma patients: a retrospective analysis. Journal of Clinical Oncology. 2019;37(15_suppl):e20000.
